{"schema_version":"secwatch.filing_event.v1","accession":"0001999480-25-000024","form_type":"8-K","ticker":"ANRO","cik":"0001999480","company_name":"Alto Neuroscience, Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.745051+00:00","generated_at":"2026-05-24T11:02:09.152950+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Alto Neuroscience FY2024 net loss $61.4M; cash $169M; two directors departing","bullets":["Net loss $61.4M for FY2024 vs $36.3M in 2023; R&D expense $47M, G&A $21.6M.","Cash and equivalents $169M as of Dec 31, 2024; expected to fund operations into 2028.","Directors Jeff Chen and Maha Radhakrishnan will not stand for re-election at 2025 annual meeting; board size to shrink from 7 to 5.","ALTO-300 Phase 2b MDD trial interim analysis positive; topline results expected mid-2026.","ALTO-203 Phase 2 MDD trial enrollment complete; topline data expected Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001999480-25-000024","json":"https://secwatch.observer/filing/0001999480-25-000024.json","markdown":"https://secwatch.observer/filing/0001999480-25-000024.md","text":"https://secwatch.observer/filing/0001999480-25-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000024/0001999480-25-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000024/alto-20250317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T11:02:09.152950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"246ac36768","claim":"Maha Radhakrishnan departed as Director at Alto Neuroscience, Inc..","evidence_excerpt":"Also on March 17, 2025, Maha Radhakrishnan, M.D. informed the Company's board of directors (the \"Board\") that she will not stand for re-election as a Class I director at the Company's 2025 Annual Meeting of Stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000024/0001999480-25-000024-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will not stand for re-election"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"dbb3a03b7e","claim":"Jeff (Po Yu) Chen departed as Director at Alto Neuroscience, Inc..","evidence_excerpt":"On March 17, 2025, Jeff (Po Yu) Chen, Ph.D. informed the Company's board of directors (the \"Board\") that he will not stand for re-election as a Class I director at the Company's 2025 Annual Meeting of Stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000024/0001999480-25-000024-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will not stand for re-election"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}